Another Dow component — Pfizer — could be following in Intel’s footsteps after the chip giant’s breakout, and traders ought to buy the drugmaker’s shares, says a technical analyst.
read more
Another Dow component — Pfizer — could be following in Intel’s footsteps after the chip giant’s breakout, and traders ought to buy the drugmaker’s shares, says a technical analyst.
read more